- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Avalere's Ryan Urgo on the Biden Administration's Options to Tackle Drug Pricing
Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, discusses possible drug pricing policy options on the table for the Biden administration to consider in a midterm election year.
Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, is one of the panel members who will discuss possible drug pricing policy options and other health care issues for the Biden administration to consider, in a talk called “Evolution of Biden’s Healthcare Agenda in an Election Year.”
Transcript
Every administration wants to tackle high drug prices. What is Biden’s plan to move forward from Build Back Better and introduce and implement policies that do address prescription drug prices?
I think that the first order of business for the administration is to see if the legislative process bears fruit before the midterm elections. And they would try to get something done on Medicare negotiation, inflation, rebate penalties, and potentially Medicare Part D redesign. If that effort fails, it would be a safe bet to expect the administration pivots towards using their regulatory authority to try to get some of these similar policies through, but that would be through the confines of a demonstration through CMMI [Center for Medicare and Medicaid Innovation], potentially, and it would be a piecemeal effort and certainly much more limited in scope.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
